Clinical Trial: Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904195) titled 'Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.' on Aug. 27.

Brief Summary: The goal of this clinical trial is to learn whether EP-088\_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety. EP-088\_MM09 contains modified house dust mite allergens called mannan-conjugated allergoids.

The study plans to include 250 participants aged 12 to 65 years. They will have persistent, moderate to severe nasal allergy symptoms, with or without eye symptoms. Participants may also have mild or moderate allergic asthma, provided it is controlled...